Sensus Healthcare, Inc. (SRTS) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Sensus Healthcare, Inc. is a medical device company manufacturing radiation therapy devices (SRT-100, SRT-100+, SRT-100 Vision) for treating skin conditions. The company operates globally with a significant presence in the U.S. and China. It also operates a subsidiary, Sensus Healthcare Services, LLC, which provides operational healthcare services and equipment leasing to dermatology clinics under "Fair Deal Agreements."
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $3.39 million | $8.34 million |
| Gross Profit | $0.99 million | $4.35 million |
| Gross Margin | 29.4% | 53.0% |
| Net Loss | $(2.63) million | $(2.57) million |
| Net Loss Per Share (Diluted) | $(0.16) | $(0.16) |
| Cash and Cash Equivalents | $18.33 million | $19.07 million |
| Operating Cash Flow | $(3.75) million | $(2.68) million |
| Total Debt Outstanding | $0 | $0 |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 59.0% year-over-year, driven by a drop in unit sales (10 units in Q1 2026 vs. 21 units in Q1 2025). This was largely due to no sales to a historically large U.S. customer in the current period.
- Margin Compression: Gross margin fell from 53.0% to 29.4%. Management attributed this to a product mix shift toward international shipments with lower average selling prices and upfront costs associated with new "Fair Deal Agreement" placements where revenue is recognized over time.
- Expense Reduction: Operating expenses decreased 23.6% to $5.35 million. Notable reductions included R&D expenses (down 42% due to lower lobbying and development costs) and Selling & Marketing expenses (down 22.7% due to reduced tradeshow costs).
- Inventory Build: Inventories increased by $1.9 million to $16.5 million, reflecting anticipation of future sales.
Outlook, Risks, and Contingencies
- Credit Facility Default and Termination: The company was in default of its revolving credit facility with Fifth Third Bank (successor to Comerica) due to failing a minimum profitability covenant. On May 8, 2026, the company received notice that the facility will terminate effective May 20, 2026. No borrowings were outstanding at the time of default.
- Liquidity: Management believes existing cash reserves ($18.3 million) are sufficient to meet operating requirements for the next 12 months despite the loss of the credit facility.
- Legal Proceedings: The company is cooperating with a Department of Justice investigation regarding Medicare billing by a physician using Sensus devices. The company disputes any wrongdoing and cannot currently estimate potential costs.
- Tax Position: The company recorded a tax benefit of $1.6 million in Q1 2026. Management currently believes deferred tax assets are realizable based on cumulative pre-tax income over the last three years, though seasonality introduces uncertainty.
Investor Verification Checklist
- Customer Concentration: Verify the status of the historically large U.S. customer that accounted for 69% of revenue in Q1 2025 but zero sales in Q1 2026.
- Financing Alternatives: Assess the company's ability to secure new financing or extend operations without the terminated $15 million credit facility.
- DOJ Investigation: Monitor updates on the Department of Justice investigation regarding billing codes and potential liability.
- Revenue Recognition Timing: Review the impact of "Fair Deal Agreements" on future revenue recognition, as upfront costs are incurred while revenue is deferred over the lease term.
- Inventory Levels: Evaluate the $16.5 million inventory balance against current sales velocity to assess potential obsolescence or write-down risks.